8-K filed November 13, 2023, 6:59 PM ET ticker PROK CIK 0001850270

other material confidence high sentiment positive materiality 0.80

ProKidney reports positive Phase 2 data for REACT; narrows Phase 3 enrollment; appoints new CEO

PROKIDNEY CORP.

Positive interim Phase 2 data: REACT preserved kidney function up to 30 months in high-risk Stage 3b/4 diabetic CKD patients.
Phase 3 proact 1 protocol modified: eGFR range narrowed to 20-35 ml/min/1.73m2; enrollment paused until H1 2024.
Manufacturing paused due to QP audit documentation deficiencies; no safety issues; expected to resume H1 2024.
Bruce Culleton appointed CEO effective Nov 15, 2023; Tim Bertram transitions to scientific advisory role.
Cash and marketable securities $396M as of Sept 30, 2023; funding into Q4 2025.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bruce Culleton

Class III Director

PROK · PROKIDNEY CORP.

Effective: 2023-11-15
Filed: November 13, 2023, 6:59 PM ET

the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.

Departed

Tim Bertram

Director

PROK · PROKIDNEY CORP.

Effective: 2023-11-15
Successor: Bruce Culleton
Filed: November 13, 2023, 6:59 PM ET

Dr. Bertram will resign from the Board of Directors (the “Board”) of the Company.

Appointed

Bruce Culleton

Chief Executive Officer

PROK · PROKIDNEY CORP.

Effective: 2023-11-15
Filed: November 13, 2023, 6:59 PM ET

the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.

Departed

Tim Bertram

Chief Executive Officer

PROK · PROKIDNEY CORP.

Effective: 2023-11-15
Successor: Bruce Culleton
Filed: November 13, 2023, 6:59 PM ET

the board of directors (the “Board”) of ProKidney Corp. (the “Company”) approved the termination, without cause, of Tim Bertram, Ph.D., Chief Executive Officer of the Company, effective November 15, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bruce Culleton was appointed as Class III Director at PROKIDNEY CORP..

Action: appointed
Role: Class III Director

Exact text from the filing

the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Tim Bertram departed as Director at PROKIDNEY CORP..

Action: resign
Role: Director

Exact text from the filing

Dr. Bertram will resign from the Board of Directors (the “Board”) of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Bruce Culleton was appointed as Chief Executive Officer at PROKIDNEY CORP..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Tim Bertram departed as Chief Executive Officer at PROKIDNEY CORP..

Action: terminated without cause
Role: Chief Executive Officer

Exact text from the filing

the board of directors (the “Board”) of ProKidney Corp. (the “Company”) approved the termination, without cause, of Tim Bertram, Ph.D., Chief Executive Officer of the Company, effective November 15, 2023

View on SEC.gov

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0001193125-23-276225

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.